A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
City of Hope Medical Center
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
University Health Network, Toronto
National Cancer Institute (NCI)
Blueprint Medicines Corporation
M.D. Anderson Cancer Center
Toray Industries, Inc
University of Pittsburgh
Loma Linda University
AstraZeneca
Ohio State University Comprehensive Cancer Center
Washington University School of Medicine
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Eli Lilly and Company
University Medical Center Groningen
Kyowa Kirin Co., Ltd.
EMD Serono
Emory University
Mersana Therapeutics
University of Pittsburgh
AbbVie
Ruijin Hospital
Imperial College Healthcare NHS Trust
Memorial Sloan Kettering Cancer Center
Syros Pharmaceuticals
EMD Serono
Massachusetts General Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of California, Irvine
National Institutes of Health Clinical Center (CC)
Celgene
National Institutes of Health Clinical Center (CC)
Celgene
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fox Chase Cancer Center
Mayo Clinic
GOG Foundation
Fox Chase Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The Netherlands Cancer Institute
University of Chicago
Wake Forest University Health Sciences
Ohio State University Comprehensive Cancer Center